Stocks and Investing Stocks and Investing
Fri, August 6, 2021

Jonathan Wolleben Maintained (BCRX) at Buy with Increased Target to $23 on, Aug 6th, 2021


Published on 2024-10-27 17:32:06 - WOPRAI, Jonathan Wolleben
  Print publication without navigation


Jonathan Wolleben of JMP Securities, Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Buy with Increased Target from $22 to $23 on, Aug 6th, 2021.

Jonathan has made no other calls on BCRX in the last 4 months.



There is 1 other peer that has a rating on BCRX. Out of the 1 peers that are also analyzing BCRX, 0 agree with Jonathan's Rating of Hold.



This is the rating of the analyst that currently disagrees with Jonathan


  • Brian Cheng of "Cantor Fitzgerald" Initiated at Buy and Held Target at $21 on, Tuesday, August 3rd, 2021

Contributing Sources